Novartis AG (NYSE: NVS) announced that its drug Rhapsido met primary endpoints in a Phase III trial for treating chronic inducible urticaria, a condition where everyday triggers cause itchy skin welts.

The RemIND trial tested Rhapsido across three common subtypes of chronic inducible urticaria: symptomatic dermographism, cold urticaria, and cholinergic urticaria. At 12 weeks, patients taking Rhapsido 25 mg twice daily showed higher complete response rates compared to placebo across all three subtypes.

For symptomatic dermographism, 29.3% of patients achieved complete response versus 14.0% on placebo. Cold urticaria patients showed 56.3% complete response compared to 14.6% for placebo. Cholinergic urticaria patients had 29.3% complete response versus 15.8% on placebo.

The company presented these results at the European Academy of Allergy and Clinical Immunology Congress. Novartis stated this represents the first treatment to demonstrate efficacy in a global Phase III chronic inducible urticaria trial.

Novartis has submitted a supplemental New Drug Application to the FDA for approval of Rhapsido to treat symptomatic dermographism and plans additional regulatory filings globally through 2026.

Rhapsido is currently approved in the United States, European Union, China and other countries for treating chronic spontaneous urticaria in adults who respond inadequately to antihistamines.

The information is based on a company press release statement.